Phathom begins Phase 3 trial of VOQUEZNA as — needed dosing in non — erosive GERD patients

Phathom Pharmaceuticals began screening patients for a registrational Phase 3 trial of VOQUEZNA as-needed dosing in non-erosive GERD. The study aims to show rapid, sustained relief of heartburn episodes with on-demand use, supporting a potential U.S. label expansion. Earlier Phase 2 data were positive; Phase 3 topline results are expected in Q1 2028. The trial plans to enroll about 500 adults in the U.S., comparing VOQUEZNA 10 mg versus placebo over 24 weeks. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief via (Ref. ID: 202609290800PRIMZONEFULLFEED9835504) on September 29, 2026, and is solely responsible for the information contained therein. (C)